Merck Global Health Innovation Fund

Merck Global Health Innovation Fund Research

Investment Thesis

Merck Global Health Innovation Fund (MGHIF, also known as GHI Fund or GHIF) is the corporate venture capital arm of Merck & Co. (known as MSD outside the US and Canada). Founded in 2010, GHI is a growth investor that partners with innovative digital health and data science companies that facilitate and optimize biopharmaceutical operations with the goal of improving patient care. The fund is explicitly therapeutic-and-brand-agnostic, meaning it invests based on the strength of the technology and business rather than alignment to a specific Merck drug or franchise. GHI positions itself as bringing a "venture mentality" combined with the benefits of a strategic corporate investor: deep digital health domain expertise, a nimble and accessible investment team, and connections into Merck's global operations across more than 140 countries (clinical development, commercialization, supply chain, marketing, and regulatory compliance).

GHI organizes its thesis around four investment areas:

• Drug Discovery & Clinical Development — digital data networks and analytics for target identification, NCE/NME drug discovery platforms, novel delivery platforms, synthetic biology, molecular diagnostics, digital pathology and radiology, digital biomarkers and remote monitoring, blood-based diagnostics and sampling, and eClinical/patient recruitment/data management platforms.
• Manufacturing, Supply Chain, & IT — digital supply chain, plant-to-patient visibility, connected floors and labs, data and application integration, enterprise privacy and security, enterprise architecture, quantum computing, and blockchain.
• Access to Medicine & Patient Support — social determinants of health, patient-centric care, commercial data analytics, clinical decision support and evidence-based medicine, provider communications, remote monitoring, and patient support/care management.
• Real World Evidence Generation — data and analytics to power real-world evidence, scaled data networks, multimodal longitudinal data, identifying care gaps, population health screening, and access to clinical trials.

Stage Focus

GHI invests across a full spectrum from early stage through growth stage, structured into three explicit tiers:

• Accelerators (early stage, up to 20% ownership): invests up to $2M in early-stage companies through three in-house accelerator programs — Merck Digital Science Studio, Merck IDEA Studios Singapore, and Merck IDEA Studios Berlin.
• Venture Capital (Series B or Series C, up to 20% ownership): typically invests up to $10M equity in areas aligned with Merck's business needs.
• Growth Capital (up to 30% ownership): invests more than $10M equity when the target business is signing a multiyear, multimillion-dollar services contract with Merck.

Check Size

Based on the three-tier structure: roughly $250K–$2M at the accelerator/early stage, and up to $10M for typical Series B/C venture investments, scaling above $10M for growth-stage/strategic-contract deals. Individual round sizes GHI has participated in span from ~$5M seed rounds to $37M+ Series B rounds.

Lead Tendency

Mixed. GHI has led rounds outright (e.g., Ash's $10M Series A in October 2024, Antidote's $11M round in 2017), co-led rounds alongside other VCs (e.g., Faro AI's $37.3M Series B co-led with S32 in August 2026), and also participated as a strategic investor in syndicates led by others (e.g., Livongo's Series E led by General Catalyst and Kinnevik; DropGenie's Seed+ round led by Skeleton Key).

Recent Activity

GHI remains an active investor as of September 2026, with recent transactions including:

• August 2026: Co-led Faro AI's $37.3M Series B (with S32) to scale agentic AI across clinical development.
• June 2026: New investor in DropGenie's Seed+ financing (led by Skeleton Key) to commercialize its miniaturized gene-editing platform.
• October 2024: Led Ash's $10M Series A to scale at-home lab testing.
• July 2024: Led N-Power Medicine's Series B (bringing its total funding to $72M) to bolster access to community oncology clinical trials.
• June 2024: Made a strategic investment in Qure.ai's Series D round to boost healthcare AI.

Third-party trackers (Tracxn, as of September 2026) count GHI as having made 2 new investments in the trailing period, consistent with an actively deploying fund out of its $600M evergreen structure.

Portfolio Highlights

GHI's active portfolio spans 40+ digital health, data science, and biotech companies, including: PathAI (AI-assisted pathology diagnostics), Datavant (health data interoperability), TriNetX (real-world evidence research network), Unite Us (coordinated health/social care networks), Transcarent (consumer health navigation platform), Verana Health (clinical databases), Saama (AI clinical analytics), BigHat Bio and Verge Genomics (ML-driven drug discovery), Evaxion Biotech (AI-Immunology vaccine platform), Emerald Cloud Lab (remote-controlled robotic life-science lab), WellDoc (FDA-cleared diabetes management app), and Qure.ai (AI radiology reporting).

The fund's alumni page lists numerous realized exits, including several IPOs (e.g., Livongo/Teladoc-related, Tabula Rasa, Definitive Healthcare-adjacent names) and trade sales to strategics such as Philips (clinical workflow), Optum (healthcare informatics), Boston Scientific (cardiovascular remote monitoring), WebMD (patient/physician engagement, two separate companies), Quest Diagnostics, Bio-Techne, Vocera, OpenText, and Phreesia (2023). This is a fund with a long realized track record dating to 2010.

Team

GHI is led by a stable, largely founding team that has been in place since the fund's 2010 inception, supplemented by more recent senior hires:

• Bill Taranto, President & General Partner — Founding partner since 2010; 30+ years of healthcare experience, 20+ in healthcare investing; previously 18 years at Johnson & Johnson (venture capital, marketing, sales, business development) and 8 years in investment banking; chairs the Merck Innovative Ventures Board and the GHI Fund LLC Management Board.
• Dave Stevenson, COO & Managing Director — Founding partner since 2010; manages GHI portfolio and operations; previously Head of U.S. Strategy at Sanofi and built Novartis's first clinical trial management system.
• David Rubin, Ph.D., Managing Director — Founding partner since 2010; focused on digital health and precision medicine, primarily oncology; formerly led portfolio management at Merck Research Labs and was CEO of Cognia Corporation.
• Joe Volpe, Managing Director — Founding partner since 2010; focused on Health IT, manufacturing/supply chain, and healthcare data/systems platforms; previously 20+ years at Johnson & Johnson across Consumer, Pharma, and Device.
• Joel Krikston, Managing Director, Venture Investments & Head of Strategic Innovation Alliances — Joined 2013; focused on Oncology, Vaccines, and Infectious Disease; previously Investment Principal at Johnson & Johnson Development Corporation and an investment banker (BNP Paribas, JPMorgan, ABN Amro).
• Vishal Sahni, Investment Director — Precision medicine and diagnostics focus; previously Lundbeck Corporate Business Development & Strategy and Director at the MRL Discovery Centre.
• Hanqing Li, Ph.D., Investment Director — Digital health focus; previously a technical specialist at Finnegan, Henderson, Farabow, Garrett & Dunner (patent law) and R&D at Quantgene.
• Mike Morgan, Principal — Joined 2021; previously Senior Manager in Accenture's Life Sciences Strategy Practice.
• Susie Oblak, Executive Director, Strategic Innovation Alliances — Joined 2024; previously SVP Technology Partnerships at Komodo Health and UK General Manager for Big Health.
• Alba Zurriaga Carda, Investment Director — Digital health and enabling technologies; previously Director of Investments at Sanofi Ventures and Global Head of Innovation Strategy at 500 Global.

Decision Process

Corporate venture structure with an investment-committee-style governance layer: Bill Taranto chairs both the Merck Innovative Ventures Board (which manages identification and funding of portfolio businesses) and the GHI Fund LLC Management Board. Deal sourcing and diligence is distributed across Managing Directors and Investment Directors by therapeutic/functional focus area (oncology/vaccines, precision medicine/diagnostics, manufacturing/supply chain, etc.), consistent with an investment-committee decision process typical of large corporate VC arms.

Founder Preferences

GHI backs companies whose technology has a clear line of sight to improving biopharmaceutical operations or patient outcomes — digital health, data science, and enabling-technology founders building for drug discovery, clinical development, supply chain/manufacturing, patient access, or real-world evidence generation. The fund explicitly avoids being tied to a specific Merck brand or therapeutic area, so it will back founders solving horizontal problems (interoperability, AI-enabled diagnostics, clinical trial infrastructure) as readily as those in oncology or vaccines, Merck's core categories.

Geographic Focus

Primarily United States-based portfolio and team (New Jersey/New York), with selective international investments — e.g., Base Immune (UK) — and accelerator programs extending GHI's reach into Singapore and Berlin via Merck IDEA Studios. Through Merck's global operations, GHI offers portfolio companies commercialization connections in more than 140 countries.